What Happened?
Shares of healthcare diagnostics company QuidelOrtho (NASDAQ: QDEL) jumped 34.7% in the afternoon session after reports revealed that the company is considering the sale of its point-of-care testing business for about $1.5 billion.
According to reports, QuidelOrtho is evaluating bids from private equity firms for the unit, which is known for its rapid COVID-19 antigen tests. The potential sale is intended to help reduce the company's $3.8 billion debt burden, which largely stems from its 2022 acquisition of Ortho Clinical Diagnostics.
An analyst at Jefferies viewed a potential sale as a net positive for the company, though the firm is awaiting final details. The stock's significant jump followed the news breaking over the weekend.
Is now the time to buy QuidelOrtho? Access our full analysis report here, it’s free.
What Is The Market Telling Us
QuidelOrtho’s shares are extremely volatile and have had 50 moves greater than 5% over the last year. But moves this big are rare even for QuidelOrtho and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 7 months ago when the stock gained 14.9% on the news that the company's President and CEO, Brian Blaser, purchased 23,500 shares of company stock.
The transaction, valued at approximately $501,490, was seen by investors as a strong vote of confidence in the company's future. Such a substantial purchase by a top executive often suggests a belief that the company is heading in the right direction or that its stock is undervalued.
According to filings, the acquisition increased the CEO's holdings in the company by nearly 390%. This significant boost in ownership underscored his commitment and positive outlook, which resonated with the market.
QuidelOrtho is down 35.4% since the beginning of the year, and at $18.60 per share, it is trading 47.4% below its 52-week high of $35.38 from January 2026. Investors who bought $1,000 worth of QuidelOrtho’s shares 5 years ago would now be looking at only $140.74.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
